J-Pharma Presented the latest findings on LAT1 inhibitor NANVURANLAT (development code: JPH203) at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI2024)

January 22, 2024
J-Pharma Co., Ltd.

For Print

J-Pharma Co. Ltd. (Headquarters: Yokohama, Kanagawa Prefecture, President & CEO Masuhiro Yoshitake) announces the latest findings on its LAT1 inhibitor Nanvuranlat which were presented in a poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2024) held in San Francisco, California, USA.

1. Poster Session:
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
2. Date and Time: January 19, 2024, 12:30 – 14:00 (local time)
3. Abstract Number: 483
4. Abstract Title
Treatment outcomes by stratifying the N-acetyl transferase 2 phenotype in pre-treated
patients with advanced refractory biliary tract cancer treated an ad-hoc analysis of a
randomized, double-blind, placebo-controlled phase 2 study.
5. First Presenter
Dr. Naohiro Okano, M.D., Ph.D
Assistant Professor, Department of Medical Oncology, School of Medicine,
Kyorin University Faculty of Medicine

[For further information, please contact.]
J-Pharma Co., Ltd.,
Administration Department, Public Relations
TEL: 045-506-1155
FAX: 045-506-1156
Mail: info@j-pharma.com